Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PSMA PET/CT-Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus.

European journal of nuclear medicine and molecular imaging·2026
Same author

Epidermal radionuclide therapy with rhenium-188 in non-melanoma skin cancer: a short narrative review.

Frontiers in medicine·2026
Same author

Correction to: Dynamic PSMA-PET for metastasis profiling in prostate cancer: a potential new approach to predict response to therapy.

European journal of nuclear medicine and molecular imaging·2026
Same author

PSA persistence in the PSMA PET era: reassessing a risk factor after radical prostatectomy.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Dynamic PSMA-PET for metastasis profiling in prostate cancer: a potential new approach to predict response to therapy.

European journal of nuclear medicine and molecular imaging·2026

Related Experiment Video

Updated: Oct 4, 2025

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:05

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

727

Theragnostics in prostate cancer.

Andrea Farolfi1, Riccardo Mei2, Sakaria Ali3

  • 1Division of Nuclear Medicine, IRCCS University Hospital of Bologna, Bologna, Italy - andrea.farolfi3@gmail.com.

The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of
|February 8, 2022
PubMed
Summary
This summary is machine-generated.

Prostate-specific membrane antigen (PSMA) theragnostics show promise for precision medicine in prostate cancer (PCa). PSMA-ligand PET imaging and [177Lu]Lu-PSMA-617 therapy improve survival for metastatic castration-resistant PCa.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

815

Related Experiment Videos

Last Updated: Oct 4, 2025

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:05

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

727
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

815

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceutical Therapy

Background:

  • Prostate-specific membrane antigen (PSMA) is a validated target for prostate cancer (PCa) theragnostics.
  • PSMA-targeted therapies offer a pathway for precision medicine in PCa management.
  • Recent FDA approvals highlight the growing clinical significance of PSMA-based diagnostics and therapeutics.

Purpose of the Study:

  • To review recent advancements in PSMA theragnostics for prostate cancer.
  • To focus on current clinical applications and future directions in PSMA-based PCa management.
  • To emphasize the role of PSMA-ligand PET imaging in patient selection for therapy.

Main Methods:

  • Comprehensive literature review of PSMA theragnostics in prostate cancer.
  • Analysis of clinical trial data, including the VISION trial for [177Lu]Lu-PSMA-617.
  • Discussion of recent FDA approvals for PSMA PET imaging agents.

Main Results:

  • PSMA-ligand PET imaging is crucial for characterizing tumors and determining eligibility for PSMA radioligand therapy.
  • [177Lu]Lu-PSMA-617 therapy demonstrated significant improvements in overall survival and radiographic progression-free survival in metastatic castration-resistant PCa (mCRPC).
  • The VISION trial results support the efficacy of [177Lu]Lu-PSMA-617 in progressive mCRPC.

Conclusions:

  • PSMA theragnostics represent a significant advancement in the precision medicine approach to prostate cancer.
  • PSMA-targeted imaging and therapy are becoming integral components of PCa management.
  • Continued research and development in PSMA theragnostics hold promise for further improving patient outcomes.